← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	1,627	+1,627	–	$139B
2	2 Amgen AMGN $235B	1,032	+1,032	–	$59.9B
3	3 Eli Lilly LLY $1.12T	975	+975	–	$40.4B
4	4 Becton Dickinson BDX $52.8B	796	+796	–	$15.9B
5	5 Teva Pharmaceutical Industries Limited TEVA $47.9B	744	+744	–	$16.6B
6	6 McKesson MCK $117B	678	+678	–	$22.3B
7	7 Conagra Brands CAG $6.77B	606	+606	–	$10.2B
8	8 DaVita DVA $12.1B	431	+431	–	$11.2B
9	9 Novo Nordisk NVO $173B	411	+411	–	$5.81B
10	10 Regeneron Pharmaceuticals REGN $82B	371	+371	–	$17B
11	11 AstraZeneca AZN $258B	331	+331	–	$5.85B
12	12 ResMed RMD $34.1B	313	+313	–	$3.93B
13	13 Herbalife HLF $1.53B	280	+280	–	$4.91B
14	14 Accendra Health ACH $20.1M	228	+228	–	$2.15B
15	15 West Pharmaceutical WST $27B	197	+197	–	$2.19B
16	16 DELISTED WW International WW	168	+168	–	$2.59B
17	17 Dr. Reddy's Laboratories RDY $10.8B	149	+149	–	$854M
18	18 Fresenius Medical Care FMS $11.8B	147	+147	–	$664M
19	19 Medifast MED $135M	144	+144	–	$292M
20	20 Tootsie Roll Industries TR $2.88B	140	+140	–	$466M
21	21 MannKind Corp MNKD $1.03B	135	+135	–	$350M
22	ARNA 22 DELISTED Arena Pharmaceuticals Inc ARNA	134	+134	–	$787M
23	23 Opko Health OPK $1.2B	131	+131	–	$328M
24	24 Lexicon Pharmaceuticals LXRX $734M	103	+103	–	$1.02B
25	25 Madrigal Pharmaceuticals MDGL $10.6B	84	+84	–	$249M